TWST Earnings

TWST reported its FY2026Q1 earnings on 2026-02-02, showcasing a revenue of 0.00 against an estimate of 101.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.47 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following TWST's FY2026Q1 earnings announcement on 2026-02-02, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, TWST's stock price tends to shift by an average of +1.86% in the 10 days leading up to earnings and +2.96% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate TWST’s annual revenue to reach 100.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -0.91% and EPS estimates Revise Downward by -0.41% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between TWST's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Downward by -0.91%, while EPS estimates moved Revise Downward by -0.41% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, TWST's stock price typically moves by +1.86% in the 10 days before its earnings and +2.96% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.00 and revenue of 100.00M.

The earnings call summary and Q&A indicate a positive sentiment. The company shows strong revenue growth guidance across all segments, improving gross margins, and a strategic focus on AI synergies. Despite some guidance below expectations, management remains optimistic about long-term growth, especially in NGS and Biopharma. The expected breakeven point for adjusted EBITDA and new product launches further support a positive outlook. The market cap suggests a moderate reaction, leading to a predicted positive stock price movement of 2% to 8% over the next two weeks.